Analytical Lens: Exploring Standard BioTools Inc (LAB)’s Financial Story Through Ratios

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Standard BioTools Inc (NASDAQ: LAB) was $1.82 for the day, up 3.41% from the previous closing price of $1.76. In other words, the price has increased by $3.41 from its previous closing price. On the day, 0.87 million shares were traded. LAB stock price reached its highest trading level at $1.84 during the session, while it also had its lowest trading level at $1.73.

Ratios:

Our analysis of LAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.06.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.

On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.

On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 12 ’24 when Black Jeffrey G. bought 57,971 shares for $2.12 per share.

Taich Adam bought 45,851 shares of LAB for $91,725 on Sep 09 ’24. On Aug 27 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 250,000 shares for $2.19 each. As a result, the insider paid 546,750 and bolstered with 54,025,821 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 677511424 and an Enterprise Value of 222703648. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.49 while its Price-to-Book (P/B) ratio in mrq is 1.38. Its current Enterprise Value per Revenue stands at 1.428 whereas that against EBITDA is -1.948.

Stock Price History:

Over the past 52 weeks, LAB has reached a high of $3.04, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is -1.16%, while the 200-Day Moving Average is calculated to be -15.79%.

Shares Statistics:

LAB traded an average of 1.82M shares per day over the past three months and 1421810 shares per day over the past ten days. A total of 372.26M shares are outstanding, with a floating share count of 360.22M. Insiders hold about 3.23% of the company’s shares, while institutions hold 75.17% stake in the company. Shares short for LAB as of 1731628800 were 14682662 with a Short Ratio of 8.07, compared to 1728950400 on 21331304. Therefore, it implies a Short% of Shares Outstanding of 14682662 and a Short% of Float of 8.1.

Most Popular